Iridium
    Je lijkt een browser te gebruiken die niet wordt ondersteund

    Verouderde browsers kunnen je computer blootstellen aan veiligheidsrisico's. Om onze site optimaal te kunnen gebruiken, moet je upgraden naar een nieuwere browser.

    Voor meer informatie of vragen kan je contact opnemen met CTO via cto(at)gza.be of op het nummer 03 443 37 59.

     

    OPEN VOOR INCLUSIE

     

    29/09/2021 - OligoRARE -Stereotactic bodyradiotherapy in addition to standard of care tretment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial

     

    06/2021 - OligoCare E²-RADIatE -OligoCare: A pragmatic observational cohort study to evaluate radical radiotherapy for oligo-metastatic cancer patients

     

    09/02/2021 - DART- Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial


    26/01/2021 - DEBIO 1143-301- A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).


    14/12/2020 - EORTC-1635-BTG- "IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? The I-WOT study"


    09/12/2020 - EORTC1740- Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer


    09/2020 - ENGOT-cx11/MK3475-A18- A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer


    06/2020 - IMMUNO SABR- Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non small cell lung cancer.


    08/05/2019 - PEGASUS- A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.


    25/03-2019 - ROBOMET- Improving quality of life with stereotactic Radiation oncology for Bone metastates.


    25/03/2019 - SAVE- A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.


    04/03/2019 - DOSIS RCT-SPINE SBRT- Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial


    IORT PARTIAL BREAST RT- Oncological outcome and cosmesis after intraoperative partial breast irradiation in early stage breast cancer patients: a prospective observational study.


    SBRT LEVERMETASTASEN- National registration of patients with liver metastases treated with stereotactic body radiation therapy.

     

    GESLOTEN VOOR INCLUSIE

     

    13/12/2018 - CHEERS- CHEckpoint inhibition in combination with an immunoboost of External body Radiotherapy in Solid tumors: CHEERS-trial. Een bestralingsboost na 4 cycli immuuntherapie.

    23/10/2018 - EORTC1709- A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.


    10/08/2018 - STORM- PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM)


    11/07/2018 - ROAM-EORTC1308-ROG- Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial.


    23/05/2017 - PART-CTOR17001UZL- Elective Para-Aortic Radiotherapy (PART) for pN1 prostate cancer: a phase 2 trial using Arc Therapy (IMAT/VMAT)


    30/03/2016 - ATLAS - 56021927PCR3003- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy


    01/01/2016 - ADJ RT BLAASCA UZ GENT- Adjuvant radiotherapy after cystectomy for patients with muscle invasive bladder cancer: a phase II trial.


    • Iridium Netwerk vzw • Oosterveldlaan 22 • 2610 Antwerpen • BE 0885.546.553 RPR Antwerpen • +32 3 443 37 37 • secretariaat@iridiumnetwerk.be • www.iridiumnetwerk.be
      AZ Klina • AZ Monica • AZ Nikolaas • AZ Rivierenland • AZ Voorkempen • GZA Ziekenhuizen • UZA • ZNA

    • Disclaimer
    • Cookies
    • Privacy